DiaMedica Therapeutics Reports Clinical Milestones and Long-Term Cash Runway Through 2027
DiaMedica Therapeutics (DMAC) has announced significant progress in its clinical pipeline, specifically noting the completion of enrollment for the first two cohorts in its investigator-sponsored Phase II study regarding early-onset fetal growth restriction (FGR). The company is also moving forward with its ReMEDy2 program, with an interim analysis expected in the first quarter of 2027. From a financial perspective, management expressed confidence in the company's liquidity, stating that current cash reserves are projected to fund operations into the fourth quarter of 2027. This extended runway provides stability as the company approaches critical clinical data readouts.
Tickers: $DMAC
Topics: clinical milestones enrollment completion fetal growth restriction Phase II study